Welcome to our dedicated page for Siga Technologie SEC filings (Ticker: SIGA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Government contracts, milestone payments, and biodefense stockpile deliveries make SIGA Technologies disclosures uniquely complex. If you have ever typed “SIGA Technologies SEC filings explained simply” or hunted for the latest BARDA award inside a “SIGA Technologies quarterly earnings report 10-Q filing,” you know how time-consuming it can be to trace TPOXX revenue or pinpoint when executives exercised options. Stock Titan’s AI removes the guesswork.
Our platform ingests every document the moment it hits EDGAR, from a routine 10-Q to an unexpected 8-K that announces fresh procurement funds. AI-powered summaries translate pharma jargon into clear language, so understanding SIGA Technologies SEC documents with AI becomes a three-minute task, not a three-hour read. Need real-time alerts for “SIGA Technologies Form 4 insider transactions real-time” or a deeper look at “SIGA Technologies executive stock transactions Form 4”? One click delivers the data, while expert commentary highlights why an insider buy might precede a material event.
Go beyond headlines with focused insights that matter to biodefense investors: contract backlog trends inside the “SIGA Technologies annual report 10-K simplified,” R&D spend trajectories across quarters, or governance details in the “SIGA Technologies proxy statement executive compensation.” You can also drill into “SIGA Technologies 8-K material events explained,” compare revenue guidance through each “SIGA Technologies earnings report filing analysis,” and monitor “SIGA Technologies insider trading Form 4 transactions” without wading through dense footnotes. With AI-powered summaries, real-time filing updates, and full coverage of every SEC form, Stock Titan turns SIGA’s specialized disclosures into actionable intelligence investors can trust.
SIGA Technologies (SIGA) reported Q3 2025 results showing lower quarterly activity amid timing of product deliveries. Revenue was $2.62 million, down from $10.01 million a year ago, with no point‑in‑time product delivery recognized in the quarter and $1.73 million from research and development services.
The quarter posted a net loss of $6.37 million versus net income of $1.34 million last year, reflecting higher self‑funded R&D and lower sales. Year to date, performance remains strong: nine‑month revenue was $90.78 million (vs. $57.25 million) and net income was $28.71 million (vs. $13.45 million). Cash and cash equivalents were $171.96 million as of September 30, 2025, after paying a $0.60 per share special dividend on May 15, 2025.
Under the 19C BARDA Contract, the company cites up to approximately $630 million of contemplated payments, with $79.1 million of 2025 revenue recognized at a point in time through September 30. The EMA initiated a referral to review Tecovirimat‑SIGA following mixed mpox trial readouts; approvals in other markets remain as stated. As of October 24, 2025, 71,611,302 shares were outstanding.
Form 4 filing overview – SIGA Technologies, Inc. (SIGA)
Executive Vice President & Chief Scientific Officer Dennis E. Hruby reported routine equity transactions dated July 1 2025.
- RSU vesting (Code M): 32,258 restricted stock units converted to common shares at a cost basis of $0.00.
- Share withholding for taxes (Code F): 10,467 shares automatically sold/withheld at $6.49 per share to satisfy statutory tax obligations.
- Net share change: +21,791 shares, increasing direct ownership to 191,047 common shares.
- The underlying RSU grant was issued on May 11 2023 and vested 50 % on July 1 2024 and the remaining 50 % on July 1 2025; no derivative units remain outstanding after this conversion.
The filing reflects standard incentive-plan vesting mechanics rather than open-market buying or discretionary selling.